{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"description":"The percentage of patients who have achieved complete response, partial response and stable disease (as per RECIST v1.1), assessed up to 49 months.","groups":[{"description":"4mg RRx-001 once weekly (QW) until progression, followed by up to 6 cycles of platinum doublet chemotherapy","id":"OG000","title":"RRx-001 + Platinum Doublet (A01-09)"},{"description":"RRx-001 weekly for 3 weeks followed by up to 6 cycles of platinum doublet chemotherapy and then RRx-001 maintenance (for patients with stable disease (SD) or better at discontinuation of platinum).","id":"OG001","title":"RRx-001 + Platinum + RRx-001 (A10)"},{"description":"Standard of Care Investigator's Choice Control Arm, treatment options of one of the following: carboplatin, etoposide, doxil, gemcitabine, vinorelbine or taxane treatments until progression or intolerable toxicity","id":"OG002","title":"Investigator's Choice (A10)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Assessed up to 49 months","title":"Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"Participants"}